Aytu Biopharma, Inc.
AYTU
$1.90
-$0.07-3.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -19.04% | -31.79% | -34.46% | -39.31% | -21.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.04% | -31.79% | -34.46% | -39.31% | -21.89% |
| Cost of Revenue | -22.40% | -44.57% | -55.63% | -60.44% | -42.70% |
| Gross Profit | -17.57% | -25.05% | -22.12% | -26.38% | -7.13% |
| SG&A Expenses | -15.90% | -28.93% | -37.83% | -40.01% | -36.38% |
| Depreciation & Amortization | -6.92% | -13.03% | -18.49% | -23.08% | -19.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.12% | -32.45% | -42.57% | -46.03% | -39.55% |
| Operating Income | -58.88% | 46.76% | 111.14% | 104.58% | 115.41% |
| Income Before Tax | 130.70% | 84.59% | 94.09% | 39.14% | 66.44% |
| Income Tax Expenses | -35.36% | 90.26% | -- | -- | -- |
| Earnings from Continuing Operations | 120.00% | 76.33% | 83.40% | 26.57% | 62.20% |
| Earnings from Discontinued Operations | 67.34% | 10.23% | -254.87% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.98% | 70.87% | 74.46% | 7.08% | 55.40% |
| EBIT | -58.88% | 46.76% | 111.14% | 104.58% | 115.41% |
| EBITDA | -34.86% | -3.18% | 338.39% | 307.46% | 171.90% |
| EPS Basic | 107.62% | 75.98% | 81.48% | 42.19% | 80.20% |
| Normalized Basic EPS | 194.74% | 111.66% | 107.36% | 61.31% | 83.71% |
| EPS Diluted | 60.74% | 56.43% | 74.94% | 42.15% | 80.18% |
| Normalized Diluted EPS | 167.93% | 105.33% | 104.72% | 61.31% | 83.71% |
| Average Basic Shares Outstanding | 15.85% | 23.76% | 38.12% | 64.11% | 85.40% |
| Average Diluted Shares Outstanding | 51.90% | 52.29% | 56.53% | 64.11% | 85.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |